Authors
Plavinski S. L.
Doctor of Medicine, Head of Educational Department1
Shabalkin P. I.
PhD, researcher2
1 - North-West State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia
2 - Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Moscow, Russia
Abstract
Îver half of a century neuroprotective drugs are widely used in treating various neurological diseases. However, with the implantation of the principles of evidence-based medicine is still no clear answer how effective each of these drugs. In this work we are using statistical methods to collate the published data on the efficacy of the three drugs – cerebrolysin,cortexin and ñellex. During the work we are faced with significant challenges in conducting the statistical data for all these drugs. The main obstacle for combining data for meta-analysis are marked differences in the design of clinical trials. We were able to find meta-analytic studies or combine data from clinical trials and conduct own statistical analysis only for cerebrolysin. Published data for cortexin and cellex are extremely heterogeneous and do not allow them to evaluate. Thus, as a result of this work we can conclude that the only evidence of the efficacy cerebrolysin has the highest level (1A) in vascular dementia and Alzheimer's disease. Unambiguous conclusion about the effectiveness ofneuroprotectivedrugsin treatment of ischemic stroke on the basis of published data can not be done, further study are needed.
Key words
cerebrolysin, cortexin, ñellex, meta-analysis
References
1. Vilensky B.S, «Modern approach to cerebrolysin administration – repeated course treatment of this medicine in patients with the history of recurrent hemispherical ischemic stroke.» Nevrologicheskij zhurnal 1 (2007): 44-46.
2. Vlasov V.V, Introduction to evidence-based medicine. Moscow: Media Sfera, 2001. Print.
3. Shamalov N.A. Stakhovskaya L.V. Burenchev D.V. et al. «The effect of cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke.» Zhurnal nevrologii i psihiatrii im. S. S. Korsakova 12 (2010): 34-37.
4. Belskaya G.N. Krilova L.G. Sokolov M.A. Izmailov I.A, «Possibilities of the treatment of speech impairment in the acute stage of ischemic stroke using neuroprotective therapy.» Zhurnal nevrologii i psihiatrii im. S. S. Korsakova 9 (2015): 60-63.
5. Uhanova T.A. Gorbunov F.E. Dement'eva E.V, « Dynamics of indicators of brain activity against the background of complex rehabilitation with Cerebral Palsy.» Zhurnal nevrologii i psihiatrii im. S. S. Korsakova 10 (2012): 28-30.
6. Semenihin D. G. Kuchaeva A. V. Karpov A. M. et al. « Additional features of correction induced by neuroleptics extrapyramidal disorders in patients with schizophrenia.» Zhurnal nevrologii i psihiatrii im. S. S. Korsakova 11 (2013): 78-80.
7. Alifirova V. M. Dadasheva M. N. Doronin B. M, «Clinical efficacy and pharmacoeconomic characteristics neuroprotection cortexin low doses in the treatment of acute ischemic stroke.» Zhurnal nevrologii i psihiatrii im. S. S. Korsakova 4 (2014): 41-46.
8. Shabanov P. D. Vostrikov V. V. Bushkova. N. V. et al. «Cortexin and metabolic activators in treating postabstinentnom syndrome.» Voenno-medicinskij zhurnal 2 (2007): 38-43.
9. Levin, O. S, Cortexin in treatment of vascular encephalopathy. In Cortexin: five years experience of domestic Neurology, Skoromets A.A. Djakonov M.M, editors. Sankt-Peterburg: Nauka, 2005. Print.
10. Levchuk, L. A, «Effect of neuroprotective drug Cortexin on the dynamics of the neuroendocrine system in individuals with organic emotional lability (asthenic) disorder.» Byulleten' ehksperimental'noj biologii i mediciny 1 (2013): 75-77.
11. Maksimova M. Yu. Bryuhov V. V. Timerbaeva S. L. et al. Small hypertensive supratentorial intracerebral hemorrhage: cerebrolysin efficiency based on the results of a randomized triple-blind, placebo-controlled study. Zhurnal nevrologii i psihiatrii im. S. S. Korsakova 1 (2009): 20-26.
12. Stahovskaya L. V. Meshkova K.S. Dadasheva M. N. «A multicenter, randomized, prospective, double-blind, placebo-controlled study of the safety and efficacy of cortexin in acute and early recovery period of hemispheric ischemic stroke.» Vestnik Rossijskoj voenno-medicinskoj akademii 1 (2012): 238-244.
13. Skorohodov A. P. Dudina A. A. Kolesnikova E. A. et al. «Neuroprotection and restoration of disturbed functions in ischemic stroke.» Consilium Medicum 2 (2014): 30-34.
14. Skoromec A. A. Stahovskaya L. V. Belkin A. A, «New features of neuroprotection in the treatment of ischemic stroke.» Zhurnal nevrologii i psihiatrii im. S. S. Korsakova 22 (2008): 32-38
15. Vorob'ev P. A. Bezmel'nicyna L. Yu. Krasnova L. S. et al. «Evaluation of medical technology applications with neuroprotective drugs and psychoactive effect: cortexin, piracetam, citicoline, cerebrolysin.» Klinicheskaya gerontologiya 11-12 (2013): 14-25.
16. Skvorcova V. I. Stahovskaya L. V. Gubskij L. V. et al. «Randomized, double-blind, placebo-controlled study of the safety and efficacy of Cerebrolysin in the treatment of ischemic stroke.» Zhurnal nevrologii i psihiatrii im. S. S. Korsakova 11 (Supplement) (2004): 51-55.
17. Skvorcova V. I. Stahovskaya L. V. Shamalov N. A. Kerbikova O. B, «Results of a multicenter safety study and efficacy of Cerebrolysin in patients with acute ischemic stroke.» Insul't 16 (2006): 41-45.
18. Chukanova E. I. Gusev E. I. Belousov D. Yu. et al. «Results of a multicenter randomized controlled clinical studies and economic treatment of acute ischemic stroke Cerebrolyzin.» Nevrologicheskij zhurnal 3 (2011): 14-37.
19. Solov'ev A. G, «Cortexin efficiency in the treatment of patients with chronic alcoholic encephalopathy and polyneuropathy.» Zhurnal nevrologii i psihiatrii im. S. S. Korsakova 4 (2010): 48-51.
20. Skorohodov A. P. Dudina A. A. Kolesnikova E. A, «A comparative study of the efficacy of a number of neuroprotective in ischemic stroke.» Zhurnal nevrologii i psihiatrii im. S. S. Korsakova 17 (Supplement) (2016): 52-56.
21. Uhanova T. A, «The effectiveness of acupuncture in combination with neuroprotective therapy in the form of hemiparetic cerebral palsy.» Zhurnal nevrologii i psihiatrii im. S. S. Korsakova 7 (2012): 28-31.
22. Uhanova T. A, «Microcurrent reflexology combined with neuroprotective in rehabilitation of patients with cerebral palsy.» Voprosy kurortologii, fizioterapii i lechebnoj fizicheskoj kul'utry 5 (2012): 33-36.
23. Havinson V. H. Morozov V. G. Rybnikov V. Yu. Zakuckij N. G, «The effectiveness of cortexin at encephalopathy.» Klinicheskaya medicina 4 (1999): 42-45.
24. Nazari Sajedeh, Mazdeh Mehrdokht, Taheri Mohammad et al. «A double-blind, placebo-controlled and randomized trial of Cerebrolysin in patients with acute ischemic stroke in Iran.» Global Advanced Research Journal of Medicine and Medical Science 5 (2015): 235-239.
25. Lang W. Stadler C. H. Poljakovic Z, et al. «A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.» Int J Stroke 2 (2013): 95-104.
26. Muresanu D. F. W. Heiss DHoemberg. V. et al. «Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.» Stroke 1 (2016): 151-159.
27. Amiri-Nikpour M. R. Nazarbaghi S. Ahmadi-Salmasi B. et al «Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke.» Neuropsychiatr Dis Treat Vol. 10 (2014): 2299-2306.
28. Chen N. Yang M. Guo J. et al. «Cerebrolysin for vascular dementia.» Cochrane Database Syst Rev. Vol. 1 (2013): CD008900.
29. Gauthier S. Proano J. V. Jia J. et al. «Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials.» Dement Geriatr Cogn Disord. 5-6 (2015): 332-347.
30. Heiss W. D. Brainin M. Bornstein N. M. et al. «Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.» Stroke 3 (2012): 630-636.
31. Ladurner, G. «Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial.» J Neural Transm (Vienna) 3 (2005): 415-428.
32. R Core Team. – R: A Language and Environment for Statistical Computing. – R Foundation for Statistical Computing, Vienna, Austria, 2015.
33. Ziganshina, L. E. «Cerebrolysin for acute ischaemic stroke.» Cochrane Database Syst Rev. 6 (2015): CD007026.
